Jun 14, 2024, 16:10
Ghassan Abou-Alfa on a paper by Arndt Vogel et al.
Ghassan Abou-Alfa, a Medical Oncologist at Memorial Sloan Kettering Cancer Center, shared a post on X:
“Final firm proof of pemigatinib open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 at ESMO Open.
Great international and successfully led teamwork of Memorial Sloan Kettering Cancer.”
Read further
Source: Ghassan Abou-Alfa/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 18, 2024, 18:36
Nov 18, 2024, 18:32
Nov 18, 2024, 18:06
Nov 18, 2024, 18:00
Nov 18, 2024, 17:40
Nov 18, 2024, 17:34